Trial Outcomes & Findings for Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution (NCT NCT03326323)

NCT ID: NCT03326323

Last Updated: 2020-01-13

Results Overview

Time it takes (hours) for platelet function to recover post-ANH to pre-procedure levels as measured by platelet aggregation.

Recruitment status

COMPLETED

Target enrollment

43 participants

Primary outcome timeframe

Baseline through 24 hours post ANH procedure

Results posted on

2020-01-13

Participant Flow

Participant milestones

Participant milestones
Measure
Patients Undergoing ANH During CABG
Patients undergoing Acute Normovolemic Hemodilution during CABG surgery. Acute Normovolemic Hemodilution: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Overall Study
STARTED
43
Overall Study
COMPLETED
40
Overall Study
NOT COMPLETED
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Patients Undergoing ANH During CABG
Patients undergoing Acute Normovolemic Hemodilution during CABG surgery. Acute Normovolemic Hemodilution: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Overall Study
Unable to receive ANH protocol
3

Baseline Characteristics

Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients Undergoing ANH During CABG
n=43 Participants
Patients undergoing Acute Normovolemic Hemodilution during CABG surgery. Acute Normovolemic Hemodilution: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Age, Continuous
66 years
STANDARD_DEVIATION 10 • n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
Sex: Female, Male
Male
38 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
6 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
Race (NIH/OMB)
White
30 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants
Region of Enrollment
United States
43 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline through 24 hours post ANH procedure

Time it takes (hours) for platelet function to recover post-ANH to pre-procedure levels as measured by platelet aggregation.

Outcome measures

Outcome measures
Measure
Patients Undergoing ANH During CABG
n=40 Participants
Patients undergoing Acute Normovolemic Hemodilution during CABG surgery. Acute Normovolemic Hemodilution: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Recovery in Platelet Function Post ANH
2 hours
Standard Deviation 30

SECONDARY outcome

Timeframe: Baseline through 24 hours post ANH procedure

Time it takes for Mean Clot Firmness (MCF) to return normal levels post-ANH as measured by ROTEM

Outcome measures

Outcome measures
Measure
Patients Undergoing ANH During CABG
n=40 Participants
Patients undergoing Acute Normovolemic Hemodilution during CABG surgery. Acute Normovolemic Hemodilution: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Recovery in Mean Clot Firmness Post ANH
18 hours
Standard Deviation 6

Adverse Events

Patients Undergoing ANH During CABG

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Eric L. Sarin MD

Inova Heart and Vascular Institute

Phone: 703-776-4138

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place